Clinical Trial

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
Investigator decision
Summary
The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Withdrawn 2026-06-16
notable Enrollment reduced: 30 -> 0 participants 2026-06-16
notable Primary completion pushed: 2031-05-01 -> 2031-08-01 2026-05-02
minor Completion pushed: 2031-05-01 -> 2031-08-01 2026-05-02
Trial Details
NCT Number NCT06902246
Lead Sponsor University of Miami
Collaborators: Bayer
Conditions Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma
Start Date 2026-08-01
Primary Completion 2031-08-01 (estimated)
Study Completion 2031-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-15